FROM YAHOO NEWS Latest news, live updates on 2024 election results OTC Markets OTCPK ? USD Nymox Pharmaceutical Corporation (NYMXF) Follow Compare 0.1000 -0.0500 (-33.33%) At close: November 5 at 3:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Nymox Announces Filing of Annual Report IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to report that it filed its Annual Report with the Security and Exchange Commission (SEC) on August 29, 2024. About NYMOX Nymox is in the process of submitting, and has submitted applications for the approval to market the Company's first in class drug NYMOZARFEX? to treat the symptoms of benign prostatic hyperplasia (BPH). BPH is one of the most common conditions affecting GlobeNewswire ? 2 months ago NYMXF -33.33% Nymox Annual Report IRVINE, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its Annual Report is and has been in progress since late February, soon after Nymox received some of its corporate documents withheld by the terminated officers and directors. Unfortunately, this has caused delays beyond the Company’s control in its completion. The Company believes that the audit will be completed soon, and it will issue its annual report as soon GlobeNewswire ? 3 months ago NYMXF -33.33% Nymox Required to Resubmit Application to DKMA IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its MAA submission to the Danish Medicines Agency (DKMA) has run out of time and in order to continue will be required to extend the MAA application to DKMA by re-submission with a new fee required. As it currently stands the application “does not meet the conditions of the Medicines Act for issuing a marketing authorization.” Although a great number of questions GlobeNewswire ? 3 months ago NYMXF -33.33% Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages IRVINE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) is pleased to report that the Bahamas Supreme Court has issued a formal Order officially putting an end to the Bahamas litigation brought by terminated ex-employees. The Order also awards to Nymox its costs incurred in defending the ill-conceived lawsuit, as well as damages Nymox has suffered as a result of the litigation. The Court order states the following: The Interim Injunctio GlobeNewswire ? 7 months ago NYMXF -33.33% Nymox December 27 Message to Shareholders IRVINE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to provide this end-of-the year message to shareholders. The Company has overall had a good year and we expect 2024 to be an even better year for our Shareholders. 2023 saw our 2nd and 3rd applications for Nymozarfex advance to the level of being accepted for review. While the outcomes from these 2 applications cannot be guaranteed, these are very solid advances for which w GlobeNewswire ? 10 months ago NYMXF -33.33% Nymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and Others IRVINE, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the California Superior Court, Orange County (OCSC) has issued an order granting Nymox’s preliminary injunction against Randall Lanham, Richard Cutler, Christopher Riley, and the Committee to Restore Nymox Shareholder Value. The Court ordered that the above defendants and their officers, agents, servants, employees, assigns, and all those acting in active concert GlobeNewswire ? 11 months ago NYMXF -33.33% $250 Million Lawsuit Filed Against AscellaHealth?by Nymox Accepted and Summons Issued in California Court IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the California Superior Court, Orange County (OCSC) has accepted on November 18, 2023 Nymox's lawsuit against AscellaHealth and issued a Summons to be served on Ascella. The lawsuit is styled Nymox Pharmaceutical Corporation vs. AscellaHealth, LLC., case No. 30-2023-01362136-CU-BT-CJ. Nymox filed its lawsuit in California Superior Court, Orange County on November GlobeNewswire ? 11 months ago NYMXF -33.33% Nymox Pharmaceutical Corporation Sues AscellaHealth For $250 Million IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- This week, Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) was forced to file a lawsuit in California Superior Court, Orange County, to protect its shareholders’ interests, as Nymox alleges that a would-be “black knight” competitor resorted to illegal and unlawful corporate espionage because it could not garner the support of enough Nymox shareholders by legitimate means. This company is Defendant AscellaHealth, LLC (“Ascella”). GlobeNewswire ? 11 months ago NYMXF -33.33% Performance Overview Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return NYMXF S&P 500 YTD -83.05% +21.24% 1-Year -90.74% +32.68% 3-Year -94.54% +23.56%
